Dicerna Pharma Raises $60 Mln
Dicerna Pharmaceuticals said Thursday it closed $60 million n an oversubscribed Series C round of financing led by new investor RA Capital. Brookside Capital, Deerfield, and Omega Funds also participated. The round also includes all five of Dicerna’s existing institutional investors: Abingworth Management, Domain Associates, Oxford Bioscience Partners, Skyline Ventures and SR One. Watertown, Mass-based Dicerna is a pharmaceutical company developing RNA interference based therapeutics.
1 August 2013•3 mins read
